Talon Therapeutics cancer news

Talon said its board authorized a review of strategic alternatives and that the company hired Goldman Sachs to provide financial advisory services. The review may lead to a possible transaction, including the merger or sale of the company. Talon said it does not plan to disclose or comment until further disclosure is deemed appropriate. As of Sept. 30, 2012, Talon had $5.6 million in cash and a nine-month operating loss of $15.5 million. ...